

T2 Biosystems, Inc.  
Form 8-K  
May 30, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 29, 2018**

**T2 BIOSYSTEMS, INC.**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>001-36571</b>	<b>20-4827488</b>
<b>(State or other jurisdiction of</b>	<b>(Commission</b>	<b>(IRS Employer</b>
<b>incorporation)</b>	<b>File Number)</b>	<b>Identification Number)</b>
<b>101 Hartwell Avenue, Lexington, Massachusetts 02421</b>		

Edgar Filing: T2 Biosystems, Inc. - Form 8-K

**(Address of principal executive offices, including Zip Code)**

**(781) 761-4646**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01. Other Events.**

On May 29, 2018, T2 Biosystems, Inc. issued a press release announcing that it received market clearance from the U.S. Food and Drug Administration (FDA) for the T2Bacteria<sup>®</sup> Panel for the direct detection of bacterial species in human whole blood specimens from patients with suspected bloodstream infections. The T2Bacteria Panel runs on the T2Dx<sup>®</sup> Instrument. The FDA-cleared T2Bacteria Panel identifies five of the most common and deadly sepsis-causing species of bacteria: *Enterococcus faecium*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus*.

A copy of the press release announcing the approval is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

Exhibit No.	Description
99.1	<u>Press Release issued May 29, 2018</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 29, 2018

**T2 BIOSYSTEMS, INC.**

By: /s/ John McDonough  
John McDonough

CEO & President